Literature DB >> 30779842

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.

Jean-Daniel Lelièvre1,2,3, Laurent Hocqueloux4.   

Abstract

We report a case of sexual transmission of human immunodeficiency virus (HIV) that occurred during treatment discontinuation in a therapeutic vaccine trial, following oral sex. Transmission occurred even though the index participant was an HIV/AIDS activist, particularly well informed about the risks and modalities of transmission. This case report highlights the risk of secondary transmission of HIV during cessation of treatment in HIV cure-related trials.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV therapeutic vaccine; analytic treatment interruption; oral sex; secondary transmission

Mesh：

Substances：

Year:  2019        PMID： 30779842      PMCID： PMC6603976          DOI： 10.1093/infdis/jiz012

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  1 in total

1.  Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.

Authors:  Jean-Daniel Lelièvre
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226
  1 in total
  25 in total

1.  Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions.

Authors:  Lynda Dee; Cheriko A Boone; David Palm; Danielle Campbell; Karine Dubé
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

Review 2.  Why and where an HIV cure is needed and how it might be achieved.

Authors:  Thumbi Ndung'u; Joseph M McCune; Steven G Deeks
Journal:  Nature       Date:  2019-12-18       Impact factor: 49.962

3.  Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.

Authors:  Marie-Angélique De Scheerder; Clarissa Van Hecke; Henrik Zetterberg; Dietmar Fuchs; Nele De Langhe; Sofie Rutsaert; Bram Vrancken; Wim Trypsteen; Ytse Noppe; Bea Van Der Gucht; Jolanda Pelgrom; Filip Van Wanzeele; Sarah Palmer; Philippe Lemey; Magnus Gisslén; Linos Vandekerckhove
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

4.  Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.

Authors:  Jean-Daniel Lelièvre
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

5.  Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.

Authors:  Karine Dubé; John Kanazawa; Chadwick Campbell; Cheriko A Boone; Allysha C Maragh-Bass; Danielle M Campbell; Moisés Agosto-Rosario; Jamila K Stockman; Dázon Dixon Diallo; Tonia Poteat; Mallory Johnson; Parya Saberi; John A Sauceda
Journal:  AIDS Res Hum Retroviruses       Date:  2021-05-31       Impact factor: 2.205

6.  Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.

Authors:  Marcos V P Gondim; Scott Sherrill-Mix; Frederic Bibollet-Ruche; Ronnie M Russell; Stephanie Trimboli; Andrew G Smith; Yingying Li; Weimin Liu; Alexa N Avitto; Julia C DeVoto; Jesse Connell; Angharad E Fenton-May; Pierre Pellegrino; Ian Williams; Emmanouil Papasavvas; Julio C C Lorenzi; D Brenda Salantes; Felicity Mampe; M Alexandra Monroy; Yehuda Z Cohen; Sonya Heath; Michael S Saag; Luis J Montaner; Ronald G Collman; Janet M Siliciano; Robert F Siliciano; Lindsey J Plenderleith; Paul M Sharp; Marina Caskey; Michel C Nussenzweig; George M Shaw; Persephone Borrow; Katharine J Bar; Beatrice H Hahn
Journal:  Sci Transl Med       Date:  2021-01-13       Impact factor: 17.956

7.  Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Authors:  Karen L Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R Mollan; Laney Henley; Angela M Stover; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-16       Impact factor: 1.723

8.  Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.

Authors:  Karine Dubé; John Kanazawa; Lynda Dee; Jeff Taylor; Danielle M Campbell; Brandon Brown; Mallory O Johnson; Parya Saberi; John A Sauceda; Jeremy Sugarman; Michael J Peluso
Journal:  HIV Res Clin Pract       Date:  2021-03-24

9.  Framing a Consent Form to Improve Consent Understanding and Determine How This Affects Willingness to Participate in HIV Cure Research: An Experimental Survey Study.

Authors:  John A Sauceda; Karine Dubé; Brandon Brown; Ashley E Pérez; Catherine E Rivas; David Evans; Celia B Fisher
Journal:  J Empir Res Hum Res Ethics       Date:  2020-12-14       Impact factor: 1.978

Review 10.  Ethics of HIV cure research: an unfinished agenda.

Authors:  Karine Dubé; John Kanazawa; Jeff Taylor; Lynda Dee; Nora Jones; Christopher Roebuck; Laurie Sylla; Michael Louella; Jan Kosmyna; David Kelly; Orbit Clanton; David Palm; Danielle M Campbell; Morénike Giwa Onaiwu; Hursch Patel; Samuel Ndukwe; Laney Henley; Mallory O Johnson; Parya Saberi; Brandon Brown; John A Sauceda; Jeremy Sugarman
Journal:  BMC Med Ethics       Date:  2021-06-30       Impact factor: 2.834
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.